DK1618128T3 - Tuberkulosevaccine med forbedret effektivitet - Google Patents

Tuberkulosevaccine med forbedret effektivitet

Info

Publication number
DK1618128T3
DK1618128T3 DK04729090.3T DK04729090T DK1618128T3 DK 1618128 T3 DK1618128 T3 DK 1618128T3 DK 04729090 T DK04729090 T DK 04729090T DK 1618128 T3 DK1618128 T3 DK 1618128T3
Authority
DK
Denmark
Prior art keywords
nucleic acid
acid molecules
improved efficacy
tuberculosis vaccine
present
Prior art date
Application number
DK04729090.3T
Other languages
English (en)
Inventor
Baerbel Raupach
Juergen Hess
Leander Grode
Stefan H E Kaufmann
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of DK1618128T3 publication Critical patent/DK1618128T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK04729090.3T 2003-04-23 2004-04-23 Tuberkulosevaccine med forbedret effektivitet DK1618128T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46464403P 2003-04-23 2003-04-23
PCT/EP2004/004345 WO2004094469A1 (en) 2003-04-23 2004-04-23 Tuberculosis vaccine with improved efficacy

Publications (1)

Publication Number Publication Date
DK1618128T3 true DK1618128T3 (da) 2010-10-18

Family

ID=33310924

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04729090.3T DK1618128T3 (da) 2003-04-23 2004-04-23 Tuberkulosevaccine med forbedret effektivitet

Country Status (23)

Country Link
US (2) US7988980B2 (da)
EP (1) EP1618128B1 (da)
JP (1) JP4662925B2 (da)
KR (1) KR101101263B1 (da)
CN (1) CN1798762B (da)
AT (1) ATE473238T1 (da)
AU (1) AU2004232485B2 (da)
BR (1) BRPI0409789B8 (da)
CA (1) CA2523084C (da)
CU (1) CU23608A3 (da)
CY (1) CY1110793T1 (da)
DE (1) DE602004028000D1 (da)
DK (1) DK1618128T3 (da)
ES (1) ES2344698T3 (da)
HR (1) HRP20100395T1 (da)
MX (1) MXPA05011360A (da)
PL (1) PL1618128T3 (da)
PT (1) PT1618128E (da)
RU (1) RU2342400C2 (da)
SI (1) SI1618128T1 (da)
UA (1) UA91180C2 (da)
WO (1) WO2004094469A1 (da)
ZA (1) ZA200508276B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2523084C (en) * 2003-04-23 2012-09-04 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Tuberculosis vaccine with improved efficacy
EP1649869A1 (en) * 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
KR101329323B1 (ko) 2004-12-01 2013-11-14 아에라스 글로벌 티비 백신 파운데이션 엔도솜을 이탈하는 능력이 보강된 재조합 비씨지 균주
US8741313B2 (en) * 2008-01-11 2014-06-03 Emory University Polypeptide vaccine and vaccination strategy against mycobacterium
WO2011031139A1 (en) 2009-09-09 2011-03-17 Universiteit Utrecht Holding B.V. An ataq protein or a part thereof as a vaccine
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
BR112013004389A2 (pt) 2010-08-27 2016-05-17 Pantarhei Bioscience Bv método imunoterapêutico para tratamento do câncer de próstata
EA026661B1 (ru) * 2010-09-20 2017-05-31 Вакцине Проект Менеджмент Гмбх Вакцина и способ вакцинации против туберкулеза
JP5986576B2 (ja) 2010-11-10 2016-09-06 ラボラトリオス レティ，エセ．エレ． 新規アジュバント
PL2654783T3 (pl) * 2010-12-21 2017-08-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rekombinowane Mycobacterium jako szczepionka
PL2656070T3 (pl) * 2010-12-21 2017-01-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Oznaczanie skuteczności żywej rekombinowanej szczepionki anty-mykobakteryjnej
RU2520078C1 (ru) * 2013-04-25 2014-06-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
EP3090757A1 (en) * 2015-05-04 2016-11-09 Vakzine Projekt Management GmbH Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer
EP3349790A1 (en) 2015-09-18 2018-07-25 Rijksuniversiteit Groningen Long chain inulin for stimulating an immune response
KR101825439B1 (ko) * 2016-04-15 2018-02-05 배재대학교 산학협력단 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법
GB2572903B (en) * 2017-04-07 2022-10-12 Chengdu Yongan Pharm Co Ltd Recombinant BCG overexpressing phoP-phoR
US10394548B2 (en) * 2017-07-25 2019-08-27 Aurora Labs Ltd. Assembling data deltas in vehicle ECUs and managing interdependencies between software versions in vehicle ECUs using tool chain
RU2678175C1 (ru) * 2018-03-16 2019-01-23 федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ гриппа им. А.А. Смородинцева" Минздрава России) Рекомбинантный штамм вируса гриппа A/PR8/HK-NS80E85A, экспрессирующий фрагменты антигенов ESAT-6 и Ag85A M.tuberculosis, для получения векторной вакцины против туберкулеза
CN111979162B (zh) * 2019-05-22 2024-02-13 上海市公共卫生临床中心 重组卡介苗菌株、其制备方法和用途
WO2021228768A1 (en) 2020-05-11 2021-11-18 Vakzine Projekt Management Gmbh Prevention of infectious diseases by modulating the immune system
WO2021228363A1 (en) 2020-05-11 2021-11-18 Vakzine Projekt Management Gmbh Prevention of infectious diseases by modulating the immune system
MX2023004103A (es) * 2020-10-09 2023-04-27 Zeria Pharm Co Ltd Uso novedoso de un extracto de mycobacterium tuberculosis.
IL310225A (en) 2021-07-22 2024-03-01 Serum Life Science Europe Gmbh Recombinant MYCOBACTERIUM as an immunotherapeutic agent for the second-line treatment of bladder carcinoma
EP4122491A1 (en) 2021-07-22 2023-01-25 Vakzine Projekt Management GmbH Recombinant microbacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2197989C2 (ru) * 1996-12-18 2003-02-10 Стэнфорд Рук Лимитед ПРИМЕНЕНИЕ Mycobacterium vaccae ДЛЯ РЕГУЛЯЦИИ ПО ТИПУ ОТРИЦАТЕЛЬНОЙ ОБРАТНОЙ СВЯЗИ Th2-АКТИВНОСТИ ИММУННОЙ СИСТЕМЫ
EP0902086A1 (en) * 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
CA2523084C (en) * 2003-04-23 2012-09-04 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Tuberculosis vaccine with improved efficacy

Also Published As

Publication number Publication date
CA2523084C (en) 2012-09-04
KR20050114281A (ko) 2005-12-05
RU2342400C2 (ru) 2008-12-27
JP2007524367A (ja) 2007-08-30
HRP20100395T1 (hr) 2010-09-30
KR101101263B1 (ko) 2012-01-04
EP1618128B1 (en) 2010-07-07
BRPI0409789B8 (pt) 2021-05-25
EP1618128A1 (en) 2006-01-25
HK1091217A1 (zh) 2007-01-12
CU23608A3 (es) 2010-12-08
RU2005136354A (ru) 2006-03-20
BRPI0409789A (pt) 2006-05-30
SI1618128T1 (sl) 2010-11-30
CA2523084A1 (en) 2004-11-04
ATE473238T1 (de) 2010-07-15
US8545854B2 (en) 2013-10-01
MXPA05011360A (es) 2005-11-28
PT1618128E (pt) 2010-10-13
CN1798762B (zh) 2010-04-28
CN1798762A (zh) 2006-07-05
WO2004094469A1 (en) 2004-11-04
AU2004232485A1 (en) 2004-11-04
US20120027794A1 (en) 2012-02-02
US7988980B2 (en) 2011-08-02
US20070134267A1 (en) 2007-06-14
PL1618128T3 (pl) 2010-12-31
BRPI0409789B1 (pt) 2018-10-16
CY1110793T1 (el) 2015-06-10
JP4662925B2 (ja) 2011-03-30
AU2004232485B2 (en) 2009-11-26
UA91180C2 (ru) 2010-07-12
ZA200508276B (en) 2006-06-28
DE602004028000D1 (de) 2010-08-19
ES2344698T3 (es) 2010-09-03

Similar Documents

Publication Publication Date Title
SI1618128T1 (sl) Cepivo proti tuberkolozi z izboljšano učinkovitostjo
DK1007686T3 (da) Tuberkulosevaccine
NO20072470L (no) Malariaigangsetter/forsterkervaksine
CA2817709C (en) Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
WO2008140812A3 (en) Compositions and methods comprising klk3, psca, or folh1 antigen
MX351247B (es) Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
DK1487485T3 (da) Imidazoquinolinadjuvanser til DNA-vacciner
CY2013026I1 (el) Πολυπεπτιδιου-εμβολια για ευρεια προστασια εναντι υπερ-λοιμογονων μηνιγγιοκοκκικων γενεαλογικων σειρων
MY150226A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
PL1881845T3 (pl) Szczepionki przeciwko wirusowi Nipah
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
WO2007024947A3 (en) Canine influenza vaccines
ATE321853T1 (de) Humanische pellino-polypeptide
EA200702254A1 (ru) Вакцинная композиция, содержащая в-субъединицу термолабильного токсина e.coli и антиген и адъювант
ATE420658T1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine
UA101140C2 (ru) Комбинация рекомбинантной микобактерии и биологически активного агента как вакцины
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
DK1664102T3 (da) Isoleret photoprotein mtclytin, samt dets anvendelse
GB0409559D0 (en) Polypeptide
BR0308180A (pt) protéinas de superfìcie de leptospira
FR2874025B1 (fr) Nouvelles proteines permettant, notamment, la mise en evidence in vitro et la prevention des infections a legionella pneumophila
UA103306C2 (en) Normal;heading 1;heading 2;heading 3;HUMAN C-FMS ANTIGEN BINDING PROTEINS
TW200736272A (en) Isolated chitinase, DNA, recombinant vector, recombinant chitinase and expression system thereof
MXYU04000010A (es) Vacuna de polinucleotido contra la leishmaniosis visceral y cutanea.